ArticleScientific reports2022
Active surveillance versus initial surgery in the long-term management of Bosniak IIF-IV cystic renal masses.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Diagnostic value of percutaneous sampling in Bosniak III-IV renal cysts: a systematic review and meta-analysis.The Canadian journal of urology · 2026Pooled it
- Article
- Survival Outcomes of Patients with Treated vs Actively Surveilled Bosniak III or IV Kidney Cysts: A Systematic Review.European urology open science · 2026Review
- CEUS in Atypical Renal Cystic Masses: How, When and Why.Medicina (Kaunas, Lithuania) · 2026Review
- Imaging Assessment of Complex Renal Cysts: Comparative Value of Superb Microvascular Imaging and Contrast-Enhanced Ultrasound.Journal of personalized medicine · 2026Article
- Article
- Clinical value of contrast-enhanced ultrasound combined with quantitative analysis in Bosniak ≥ II cystic renal masses.Abdominal radiology (New York) · 2025Article
- Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics.Journal of clinical medicine · 2024Review
- 2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Pathological report and prognostic meaning of Bosniak IV cysts: results from a contemporary cohort.Central European journal of urology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There may be surgical overtreatment of complex cystic renal masses (CRM). Growing evidence supports active surveillance (AS) for the management for Bosniak IIF-III CRMs. We aimed to evaluate and compare oncological and pathological outcomes of Bosniak IIF-IV CRMs treated by initial surgery (IS) or AS. We identified retrospectively 532 patients with CRM counseled during 2006-2017. IS and AS were delivered to, respectively, 1 and 286 patients in Bosniak IIF, to 54 and 85 patients in III and to 85 and 21 patients in Bosniak IV. Median follow-up was 66 months (IQR 50-96). Metastatic progression occurred for 1 (0.3%) AS patient in Bosniak IIF, 1 IS (1.8%) and 1 AS (1.2%) patient in Bosniak III and 5 IS (3.5%) patients in Bosniak IV, respectively. Overall 5-year metastasis-free survival was 98.9% and cancer-specific survival was 99.6% without statistically significant difference between IS and AS in Bosniak IIF-IV categories. AS did not increase the risk of metastatic spread or cancer-specific mortality in patients with Bosniak IIF-IV. Our data indicate AS in Bosniak IIF and III is safe. Surgery is the primary treatment for Bosniak IV due to its high malignancy rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.